Long-term efalizumab therapy for patients with moderate-to-severe, chornic plaque psoriasis: results from an Australian expanded access program

P. Foley, M. Freeman, Kurt Gebauer, D. Murrell, S. Schumack, C. Tyson, G. Varigos

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Fingerprint Dive into the research topics of 'Long-term efalizumab therapy for patients with moderate-to-severe, chornic plaque psoriasis: results from an Australian expanded access program'. Together they form a unique fingerprint.

    Medicine & Life Sciences